Meropenem

Communicable Diseases, Urinary Tract Infections, Urinary Tract Infection (UTI) + 2 more
Treatment
6 FDA approvals
9 Active Studies for Meropenem

What is Meropenem

MeropenemThe Generic name of this drug
Treatment SummaryMeropenem is an antibiotic that fights both Gram-positive and Gram-negative bacteria. It works by entering the bacterial cells and stopping them from making the components they need to survive. In 2017, a combination of meropenem and another drug called [DB12107] was approved to treat complicated urinary tract infections in adults. This medication, called Vabomere, can help relieve symptoms and clear up the infection caused by susceptible bacteria.
Merrem IVis the brand name
image of different drug pills on a surface
Meropenem Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Merrem IV
Meropenem
1996
52

Approved as Treatment by the FDA

Meropenem, commonly known as Merrem IV, is approved by the FDA for 6 uses like Urinary Tract Infection (UTI) and Bacterial Infections .
Urinary Tract Infection (UTI)
Bacterial Infections
Complicated Intra-Abdominal Infections (cIAIs)
Meningitis, Bacterial
Abdominal Infection
Communicable Diseases

Effectiveness

How Meropenem Affects PatientsMeropenem is an antibiotic that is effective against a wide range of bacteria, including both Gram-positive and Gram-negative. It works by entering the bacteria cells and disrupting their ability to make the components they need to survive, leading to their death.
How Meropenem works in the bodyMeropenem kills bacteria by blocking their ability to make cell walls. It works especially well on Gram-positive and Gram-negative bacteria, targeting specific proteins in the cells of these bacteria. Meropenem is especially effective at stopping the production of proteins in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.

When to interrupt dosage

The proposed dosage of Meropenem is contingent upon the determined affliction, including Urinary Tract Infection (UTI), complicated Bacterial Urinary Tract Infections and Meningitis, Bacterial. The measure of dosage relies upon the method of administration as demonstrated in the accompanying table.
Condition
Dosage
Administration
Communicable Diseases
, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg, 1000.0 mg, 1.0 mg/mg
, Intravenous, Injection, Injection - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, solution - Intravenous, Injection, solution
Meningitis, Bacterial
, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg, 1000.0 mg, 1.0 mg/mg
, Intravenous, Injection, Injection - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, solution - Intravenous, Injection, solution
Abdominal Infection
, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg, 1000.0 mg, 1.0 mg/mg
, Intravenous, Injection, Injection - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, solution - Intravenous, Injection, solution
Urinary Tract Infection (UTI)
, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg, 1000.0 mg, 1.0 mg/mg
, Intravenous, Injection, Injection - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, solution - Intravenous, Injection, solution
Urinary Tract Infections
, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg, 1000.0 mg, 1.0 mg/mg
, Intravenous, Injection, Injection - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, solution - Intravenous, Injection, solution

Warnings

Meropenem Contraindications
Condition
Risk Level
Notes
Anaphylactic shock
Do Not Combine
There are 20 known major drug interactions with Meropenem.
Common Meropenem Drug Interactions
Drug Name
Risk Level
Description
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Meropenem.
Abacavir
Minor
Meropenem may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Meropenem may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Meropenem may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Meropenem may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Meropenem Toxicity & Overdose RiskLarge doses of meropenem have been known to cause coordination problems, difficulty breathing, seizures, and death in mice and rats.
image of a doctor in a lab doing drug, clinical research

Meropenem Novel Uses: Which Conditions Have a Clinical Trial Featuring Meropenem?

27 active clinical trials are being conducted to investigate the potential of Meropenem to treat Meningitis, Bacterial Abdominal Infection, and Urinary Tract Infections (UTI).
Condition
Clinical Trials
Trial Phases
Meningitis, Bacterial
0 Actively Recruiting
Abdominal Infection
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Urinary Tract Infections
0 Actively Recruiting
Urinary Tract Infection (UTI)
6 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2

Meropenem Reviews: What are patients saying about Meropenem?

5Patient Review
4/7/2013
Meropenem for Pneumonia caused by Acinetobacter Bacteria
This antibiotic was very effective, but it may be too costly for some people. Make sure to use it as directed, and the infection will be cured in no time.
4.3Patient Review
10/8/2012
Meropenem for Bacterial Meningitis
This medication made me very tired. I was hospitalized after taking it for about two weeks.
4Patient Review
5/6/2009
Meropenem for Pneumonia Acquired from Being Treated In a Hospital
The only drawback was having to mix the solution each time before using it.
3.7Patient Review
10/1/2007
Meropenem for Cystic Fibrosis and Infection from Pseudomonas Bacteria
2.7Patient Review
5/30/2018
Meropenem for Complicated Skin Infection
I've been feeling really ill since taking this medication. I have no energy, and I'm constantly nauseated and have diarrhea. Not to mention the headaches. I haven't seen any benefits yet, but that's why I only gave it 2.7 stars.
1.7Patient Review
12/3/2014
Meropenem for Abscess Within the Abdomen
I'm not sure if this worked for me or not.
1Patient Review
5/1/2009
Meropenem for Cystic Fibrosis and Infection from Pseudomonas Bacteria
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about meropenem

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is meropenem the strongest antibiotic?

"Meropenem is considered a stronger antibiotic compared to other options. It is effective against many types of bacteria and can treat severe or complicated infections when other antibiotics are not effective. However, it is important to keep in mind that "stronger" antibiotics are not always the best choice."

Answered by AI

What meropenem is used for?

"Meropenem is used to treat bacterial infections. It works by killing bacteria or preventing their growth. It will not work for infections caused by viruses, such as colds or flu."

Answered by AI

What type of antibiotic is meropenem?

"Meropenem is a drug that is used to treat a broad range of serious infections in both adults and children. It is from the carbapenem family, which is a broad-spectrum antibacterial agent. Meropenem is indicated as empirical therapy, which means that it is given before the exact cause of the infection is known."

Answered by AI

Is meropenem a penicillin?

"Meropenem is an antibiotic that is effective against many of the same infections as penicillin. However, since meropenem and penicillins have similar chemical structures, doctors often avoid using meropenem in patients who are allergic to penicillin."

Answered by AI

Clinical Trials for Meropenem

Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA
The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.
Phase 4
Recruiting
Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)
Have you considered Meropenem clinical trials? We made a collection of clinical trials featuring Meropenem, we think they might fit your search criteria.Go to Trials
Image of Hospital of the University of Pennsylvania in Philadelphia, United States.

11C-Trimethoprim Imaging for Bacterial Infection

18+
All Sexes
Philadelphia, PA
Patients with suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the clinical practices of the University of Pennsylvania. Up to 30 subjects will participate in two different imaging cohorts. The Biodistribution cohort will include up to 5 patients referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution \[11C\]trimethoprim PET/CT scans over a period of approximately 2 ½ hours. The Dynamic cohort will include up to 25 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of \[11C\]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second \[11C\]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in \[11C\]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving. Patients will also undergo baseline lab tests complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and blood cultures. If these tests are done as part of clinical standard of care they will not need to be repeated for this study.
Phase 1
Waitlist Available
Hospital of the University of PennsylvaniaDavid Mankoff, MD PhD
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security